{"id":709,"date":"2025-12-03T05:50:00","date_gmt":"2025-12-03T13:50:00","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=709"},"modified":"2025-12-02T22:51:31","modified_gmt":"2025-12-03T06:51:31","slug":"fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/","title":{"rendered":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve)"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>Background and mechanism<\/strong><\/h4>\n\n\n\n<p>Spinal muscular atrophy (SMA) is an autosomal\u2011recessive neurodegenerative disorder caused by loss\u2011of\u2011function mutations in the <strong>SMN1<\/strong> gene, resulting in reduced survival motor neuron (SMN) protein, progressive motor neuron loss, and muscle atrophy. Gene\u2011replacement therapy using adeno\u2011associated virus (AAV) vectors delivers a functional copy of SMN1 to motor neurons, restoring SMN protein expression and addressing the genetic root cause of SMA.<sup>1<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The FDA approval: scope and rationale<\/strong><\/h4>\n\n\n\n<p>On 24 November 2025, the U.S. Food and Drug Administration approved <strong>Itvisma (onasemnogene abeparvovec\u2011brve)<\/strong> for <strong>adult and pediatric patients 2 years of age and older<\/strong> with a confirmed SMN1 mutation. Itvisma is an AAV\u2011based gene therapy formulated for <strong>intrathecal administration<\/strong>, enabling direct delivery to the cerebrospinal fluid and motor neurons without weight\u2011based dosing. The approval was supported by a pivotal Phase 3 trial and bridging evidence leveraging safety and efficacy data from the intravenous formulation Zolgensma (same active ingredient).<sup>1<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Key clinical evidence and durability<\/strong><\/h4>\n\n\n\n<p>Long\u2011term follow\u2011up of early onasemnogene abeparvovec trials demonstrates <strong>durable clinical benefit and a favorable safety profile<\/strong> in infants treated with the therapeutic dose, with sustained survival and preserved motor milestones up to multiple years post\u2011dosing.<sup>5<\/sup> Recent larger studies and real\u2011world analyses indicate functional improvements across a broader age and weight range, supporting intrathecal delivery for older children and adults.<sup>6<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Safety considerations<\/strong><\/h4>\n\n\n\n<p>The FDA emphasized <strong>hepatotoxicity and cardiotoxicity<\/strong> as adverse events of special interest; the Itvisma label retains warnings informed by Zolgensma data and observed hepatotoxicity in Itvisma studies. Clinicians should monitor liver function and cardiac markers per label guidance and consider comorbidities that may increase risk in adult patients.<sup>1<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Practical implications for care and access<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Administration:<\/strong> single intrathecal injection independent of patient weight, enabling treatment of older and heavier patients who were previously ineligible for intravenous dosing.<\/li>\n\n\n\n<li><strong>Regulatory designations:<\/strong> Itvisma received Fast Track, Breakthrough Therapy, Priority Review, and Orphan Drug designations, reflecting the unmet need in SMA populations beyond infancy.<\/li>\n\n\n\n<li><strong>Epidemiology:<\/strong> SMA incidence is estimated at <strong>~1 in 6,000\u201310,000 live births<\/strong>, with prevalence estimates varying by region; improved survival and newborn screening are shifting the demographic toward more adults living with SMA.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Comparative snapshot<\/strong><sup>7<\/sup><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Product<\/strong><\/td><td><strong>Route<\/strong><\/td><td><strong>Indication (summary)<\/strong><\/td><td><strong>Typical age<\/strong><\/td><\/tr><tr><td><strong>Itvisma (onasemnogene abeparvovec\u2011brve)<\/strong><\/td><td>Intrathecal<\/td><td>SMA with SMN1 mutation; \u22652 years<\/td><td>\u22652 years<\/td><\/tr><tr><td><strong>Zolgensma (onasemnogene abeparvovec\u2011xioi)<\/strong><\/td><td>Intravenous<\/td><td>SMA due to bi\u2011allelic SMN1 mutations; &lt;2 years<\/td><td>&lt;2 years<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The FDA approval of Itvisma represents a <strong>significant expansion of gene\u2011replacement therapy for SMA<\/strong>, enabling targeted intrathecal delivery to older children and adults and reinforcing the therapeutic durability observed with onasemnogene abeparvovec formulations. Ongoing surveillance and careful risk mitigation for hepatotoxicity and cardiotoxicity remain essential as real\u2011world use broadens.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>References (7)<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li>U.S. Food and Drug Administration. FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy. FDA News Release. 24 Nov 2025. <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy<\/a>\u00a0<\/li>\n\n\n\n<li>SMA Foundation. SMA Overview (SMA Overview PDF). <a href=\"https:\/\/www.smafoundation.org\/wp-content\/uploads\/2012\/03\/SMA-Overview.pdf\">https:\/\/www.smafoundation.org\/wp-content\/uploads\/2012\/03\/SMA-Overview.pdf<\/a>\u00a0<\/li>\n\n\n\n<li>Cure SMA. Check Out Cure SMA\u2019s 2024 Annual State of SMA Report. 2025. <a href=\"https:\/\/www.curesma.org\/2024-state-of-sma-report\/\">https:\/\/www.curesma.org\/2024-state-of-sma-report\/<\/a>\u00a0<\/li>\n\n\n\n<li>SpinalMuscularAtrophy.net. . Is Spinal Muscular Atrophy (SMA) Common? Statistics. <a href=\"https:\/\/spinalmuscularatrophy.net\/statistics\">https:\/\/spinalmuscularatrophy.net\/statistics<\/a>\u00a0<\/li>\n\n\n\n<li>Mendell JR, Al\u2011Zaidy S, Lehman KJ, et al. Five\u2011Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021. <a href=\"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2780250\">https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2780250<\/a>\u00a0<\/li>\n\n\n\n<li>The Lancet Regional Health \u2014 Europe. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy. <a href=\"https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(23)00236-3\/fulltext\">https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(23)00236-3\/fulltext<\/a>\u00a0<\/li>\n\n\n\n<li>U.S. Food and Drug Administration. Summary Basis for Regulatory Action \u2014 ZOLGENSMA (May 24, 2019). <a href=\"https:\/\/www.fda.gov\/media\/127961\/download\">https:\/\/www.fda.gov\/media\/127961\/download<\/a><\/li>\n<\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Background and mechanism Spinal muscular atrophy (SMA) is an autosomal\u2011recessive neurodegenerative disorder caused by loss\u2011of\u2011function mutations in the SMN1 gene, resulting in reduced survival motor neuron (SMN) protein, progressive motor neuron loss, and muscle atrophy. Gene\u2011replacement therapy using adeno\u2011associated virus (AAV) vectors delivers a functional copy of SMN1 to motor neurons, restoring SMN protein expression [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":712,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[447,450,442,446,444,451,448,443,449,445],"class_list":["post-709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-fda-gene-therapy","tag-gene-replacement-therapy","tag-intrathecal-gene-therapy","tag-itvisma-approval","tag-onasemnogene-abeparvovec","tag-pediatric-and-adult-sma","tag-rare-disease-therapy","tag-sma-clinical-update","tag-sma-treatment","tag-spinal-muscular-atrophy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec\u2011brve\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec\u2011brve\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T13:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve)\",\"datePublished\":\"2025-12-03T13:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/\"},\"wordCount\":605,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/FDA-gene-therapy-approval.jpg\",\"keywords\":[\"FDA gene therapy\",\"gene replacement therapy\",\"intrathecal gene therapy\",\"Itvisma approval\",\"onasemnogene abeparvovec\",\"pediatric and adult SMA\",\"rare disease therapy\",\"SMA clinical update\",\"SMA treatment\",\"spinal muscular atrophy\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/\",\"name\":\"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/FDA-gene-therapy-approval.jpg\",\"datePublished\":\"2025-12-03T13:50:00+00:00\",\"description\":\"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/FDA-gene-therapy-approval.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/FDA-gene-therapy-approval.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Semi\u2011realistic 1536\u00d71024 header: left two\u2011thirds show a soft\u2011focus DNA double helix, stylized AAV vector schematic, spinal cord silhouette, and motor\u2011neuron line art connecting to muscle fibers in clinical blues, teal, and muted gold; right third contains a semi\u2011transparent dark navy backer with large, high\u2011contrast white headline text reading \u201cFDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy\u201d; clean sans\u2011serif typography, subtle data\u2011visual elements, and safe margins for cropping.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/news\\\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion","description":"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec\u2011brve\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion","og_description":"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec\u2011brve\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2025-12-03T13:50:00+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve)","datePublished":"2025-12-03T13:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/"},"wordCount":605,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg","keywords":["FDA gene therapy","gene replacement therapy","intrathecal gene therapy","Itvisma approval","onasemnogene abeparvovec","pediatric and adult SMA","rare disease therapy","SMA clinical update","SMA treatment","spinal muscular atrophy"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/","name":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve) - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg","datePublished":"2025-12-03T13:50:00+00:00","description":"FDA approves gene therapy for spinal muscular atrophy, expanding one\u2011time intrathecal treatment to patients aged 2 and older.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/12\/FDA-gene-therapy-approval.jpg","width":1536,"height":1024,"caption":"Semi\u2011realistic 1536\u00d71024 header: left two\u2011thirds show a soft\u2011focus DNA double helix, stylized AAV vector schematic, spinal cord silhouette, and motor\u2011neuron line art connecting to muscle fibers in clinical blues, teal, and muted gold; right third contains a semi\u2011transparent dark navy backer with large, high\u2011contrast white headline text reading \u201cFDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy\u201d; clean sans\u2011serif typography, subtle data\u2011visual elements, and safe margins for cropping."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy-itvisma-onasemnogene-abeparvovec%e2%80%91brve\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/news\/"},{"@type":"ListItem","position":3,"name":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy \u2014 Itvisma (onasemnogene abeparvovec\u2011brve)"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=709"}],"version-history":[{"count":2,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/709\/revisions"}],"predecessor-version":[{"id":711,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/709\/revisions\/711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/712"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}